Full Press Release Details
NeOnc Technologies (Nasdaq: NTHI) to Host Investor
Conference Call to Present Dose-Escalation Results
from Full Phase 1 NEO212-01 Readout for Dosing
CALABASAS, Calif., Feb. 27, 2026 - NeOnc
Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical
company developing novel therapies for central nervous system (CNS) cancers, today announced today announced that it will host an investor
conference call and webcast on March 4, 2026, at 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time.
During the call, members of the NeOnc management
team and independent members of the Company's Scientific Advisory Board (SAB) will present initial data from the Phase 1 dose-escalation
portion of the NEO212-01 Phase 1/2 clinical trial, evaluating NeOnc's proprietary bioconjugated temozolomide (TMZ) platform in an
oral formulation for patients with CNS malignancies.
The discussion will include an update on the Phase
1 dose-escalation portion of the NEO212-01 clinical trial, including safety and toxicity data, dose-escalation observations, pharmacokinetic
findings, and planned regulatory next steps.
Featured Participants:
Conference Call Details:
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage
life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address
the persistent challenges in overcoming the blood-brain barrier. The company's NEO drug development platform has produced
a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents
have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas.
NeOnc's NEO100 and NEO212 therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track
and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University
of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc
patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology,
visit https://neonc.com
Important Cautions Regarding Forward Looking
This press release contains "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. These forward-looking statements can be identified by terminology such as "may," "will,"
"should," "intend," "expect," "plan," "budget," "forecast," "anticipate,"
"believe," "estimate," "predict," "potential," "continue," "evaluating,"
or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of
future results of operations or financial condition, or other forward-looking information. These statements reflect our current expectations
based on information available at this time, but future events may differ materially from those anticipated. We assume no obligation to
revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as
required by applicable securities laws and regulations. "NEO100" and NEO "212" are registered trademarks of NeOnc
Technologies Holdings, Inc.